Navigation Links
Liberte in Medical News

Appeals Court Affirms That J&J Stents Infringe Boston Scientific Patent; Claims Against TAXUS Liberte Dismissed

NATICK, Mass., March 31 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) announced today that the Court of Appeals for the Federal Circuit issued a decision in the Company's stent litigation with Johnson and Johnson (J&J). The Court of Appeals upheld the District C...

FDA Approves Boston Scientific's TAXUS(R) Liberte(R) Long Stent

...ived CE Mark approval in 2007. "The TAXUS liberte Long Stent offers physicians and patients distinct... "In the ATLAS Long Lesion Trial, the 38 mm TAXUS liberte Stent significantly reduced myocardial infarction ...he TAXUS((R)) Express((R)) Stent, making the TAXUS liberte Long Stent an attractive option for interventional...

Boston Scientific Announces Schedule For ACC 2009

... patients from 57 countries treated with the TAXUS liberte paclitaxel-eluting stent in real world routine int... patient resources. TAXUS, Express, Express2, liberte and PROMUS are trademarks of Boston Scientific Cor...he TAXUS Express Stent (59 patients) and the TAXUS liberte Stent (17 patients) were used as controls in the S...

OrbusNeich Files Patent Infringement Lawsuit Against Boston Scientific

...med priority; After BSC commercialized the liberte stent, Orbus became aware of the theft of its desi...BSC has been manufacturing and selling its line of liberte stent products without consideration to Orbus, the original designer of major aspects of the liberte product architecture, itself. "O...

Boston Scientific Announces Japanese Launch of Taxus(R) Liberte(R) Drug-Eluting Stent System

...t was granted yesterday by the National Health Insurance System. TAXUS liberte is the only second-generation drug-eluting stent available in Japan. Desig... coverage and drug distribution. "We are very pleased to launch TAXUS liberte as the only second-generation drug-eluting stent in Japan," said Maulik Nan...

TAXUS(R) Liberte(TM) Drug-eluting Coronary Stent System Receives CE Mark for Use in Diabetic Patients

... TAXUS liberte has more CE Mark-approved indications than any oth...Boston Scientific submitted data showing the TAXUS liberte stent has benefited diabetic patients with coronar...al-world registries. This approval means the TAXUS liberte stent system now has more CE Mark- approved indica...

HSN Is Seeing Pink with Susan G. Komen for the Cure During National Breast Cancer Awareness Month

..., Andrew Lessman, Joy Mangano, ProForm, Wolfgang Puck, Reebok, Bob Vila, Roy Yamaguchi); Fashion (e.g., Randolph Duke, Carlos Falchi, Beverly Feldman, liberte by Emanuel, LUKASTYLE, Scoop); and Electronics (e.g., Gateway, GE, JVC, Panasonic, Sharp). HSN delivers its merchandise across multiple platforms, inc...
Liberte in Medical Technology

Taxus Atlas Studies Reinforce Safety and Efficacy of Boston Scientific's Next-Generation Taxus Liberte Stent

New coronary stent features thin struts designed for more uniform drug delivery NATICK, Mass., and WASHINGTON, Oct. 12 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced comprehensive data from the TAXUS ATLAS clinical program,...

Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology

NATICK, Mass., June 04, 2007 /PRNewswire-FirstCall/ -- Boston Scientific Corporation today welcomed the publication of an article in the Journal of of Cardiology (JACC) reviewing the TAXUS ATLAS clinical trial, which evaluates the Company's second-generation TAXUS(R) Liberte(TM)(1) paclitaxel-elut...

Long Term Data Presented at EuroPCR 2009 from Randomized Study Attest to Durability of Results of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Compared to Drug-Eluting Stents

... 4.2%) and target lesion revascularization (TLR) rates (15.3% vs 13.7%) for the Genous Bio-engineered R stent compared to Boston Scientific's Taxus(R) liberte stent in high risk of restenosis patients. However, the thrombosis rate for Taxus treated patients increased from one to two years from 4.2% to 5.3%,...

Journal of American College of Cardiology Article Reports Fewer Repeat Procedures With Boston Scientific's TAXUS(R) Liberte(R) Stent

...cle reported that patients who received a TAXUS(R) liberte (R) Paclitaxel-Eluting Stent had numerically lowe... Stent. In the patients with diabetes, the TAXUS liberte Stent demonstrated a statistically significant low...ng. The JACC article reported that both the TAXUS liberte Stent and Boston Scientific's first-generation DES...

Clinical Data Reinforce Safety and Efficacy of Boston Scientific's Two Drug- Eluting Stent Platforms

...E Mark approval of a diabetic indication for TAXUS liberte in Europe." Three-year data from the SPIRIT...r Boston Scientific. "Our second-generation TAXUS liberte Stent launched earlier this month in Japan, and we...he TAXUS Express Stent (59 patients) and the TAXUS liberte Stent (17 patients) were used as controls in the S...

Abbott's Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years

...g Coronary Stent System / TAXUS(R) Liberte(TM) Paclitaxel-Eluting Coronary Stent System (TAXUS). Both TAXUS Express2 (73 percent of lesions) and TAXUS liberte (27 percent of lesions) were used as controls in the SPIRIT II trial. The data also showed that patients treated with XIENCE V continue to experience ...

Boston Scientific Submits Final Modules to FDA for Approval of Second-Generation Small Vessel and Long Lesion Stents

...itaxel-Eluting Coronary Stent System and its TAXUS liberte Long(TM) Paclitaxel-Eluting Coronary Stent System. If approved, the TAXUS liberte Atom Stent will become the Company's second 2.25 m...oved by the FDA to treat small vessels. The TAXUS liberte Long Stent is designed to be the first 38 mm drug-...

Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008

...TLAS data on small vessels and long lesions (TAXUS liberte Stent). "We are pleased to be announcing new sub...T STENT Trials: Durable Effectiveness of the TAXUS liberte Stent and Long-Term Benefit of Direct Stenting". I... e-poster session titled "Durable Benefit of TAXUS liberte vs. TAXUS Express in Small Vessels and Long Lesion...

TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent

...monstrated a low overall 3.8 percent rate of TAXUS liberte stent-related composite cardiac events, including ....3 percent and 0.9 percent respectively. The TAXUS liberte Stent also exhibited a high degree of procedural s...YMPIA reported a 4.6 percent rate of overall TAXUS liberte stent-related cardiac events and 0.8 percent defin...

Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008

...afety and effectiveness of the TAXUS Express Stent has not been established in patients with left main or three vessel disease. In the U.S., the TAXUS liberte Stent is an investigational device and is not available for sale. About Boston Scientific Boston Scientific is a worldwide developer, manufacturer...
Liberte in Biological Technology

Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009

...received approval from the FDA to market its TAXUS liberte Long(TM) paclitaxel-eluting coronary stent system,...rticle reported that patients who received a TAXUS liberte paclitaxel-eluting stent had numerically lower inc... Stent. In the patients with diabetes, the TAXUS liberte demonstrated a statistically significant lower res...

Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent

...It received CE Mark approval in 2007. "The TAXUS liberte Long Stent offers physicians and patients distinct.... "In the ATLAS Long Lesion Trial, the 38 mm TAXUS liberte Stent significantly reduced myocardial infarction ...to the TAXUS(R) Express(R) Stent, making the TAXUS liberte Long Stent an attractive option for interventional...

Angiotech Pharmaceuticals announces FDA approval of next-generation TAXUS(R) Liberte(R) Atom(TM) Stent system

...Company plans to begin a full U.S. launch of TAXUS liberte Atom next month. "The rapid adoption of the TAXU...entist Hospital, Takoma Park, Maryland. "The TAXUS liberte Atom Stent provides clear design and deliverabilit...TAXUS Atlas Small Vessel clinical trial, the TAXUS liberte Atom Stent yielded a two-year target lesion revasc...

FDA Approves Boston Scientific's Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System

...d Drug Administration (FDA) to market its TAXUS(R) liberte (R) Atom(TM) Paclitaxel-Eluting Coronary Stent Sy...Company plans to begin a full U.S. launch of TAXUS liberte Atom next month. "The rapid adoption of the ...ntist Hospital, Takoma Park, Maryland. "The TAXUS liberte Atom Stent provides clear design and deliverabilit...

Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009

...itaxel-Eluting Coronary Stent System and its TAXUS liberte Long(TM) Paclitaxel-Eluting Coronary Stent System ...Administration ("the FDA"). If approved, the TAXUS liberte Atom Stent will become BSC's second 2.25 millimete...by the FDA to treat small blood vessels. The TAXUS liberte Long Stent is designed to be the first 38 millimet...

Boston Scientific Announces First Quarter Special Items

... TAXUS(R) Express(R) and Liberte(R) Stents infringe one J&J patent and that the patent is valid. The Court also affirmed that Boston Scientific's liberte Stent infringes a second J&J patent and that the patent is valid. The Company will record an accrual of $237 million ($197 million after-tax) in ...

Boston Scientific Announces Japanese Approval for TAXUS(R) Liberte(R) Drug-Eluting Stent System

... which is expected in the coming weeks. TAXUS liberte is the only second-generation drug-eluting stent a...on coverage and drug distribution. "The TAXUS liberte Stent is the latest advance in drug-eluting stent ... therapies to the Japanese market." The TAXUS liberte Stent uses proven paclitaxel-eluting technology, w...

Video: Boston Scientific Announces FDA Approval of Second-Generation TAXUS(R) Liberte(R) Drug-Eluting Stent

...tent System. The Company plans to launch the TAXUS liberte stent early next month in the United States, follo...hich was approved by the FDA last month. The TAXUS liberte stent was launched in Europe and other internation...//www.prnewswire.com/mnr/bsci/34446/ "The TAXUS liberte stent represents our latest advance in drug-elutin...

Angiotech's Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System

... ) has received approval for the sale of its TAXUS liberte paclitaxel-eluting coronary stent system in Canada...ch the product immediately in Canada. "The TAXUS liberte Stent is a major advance in stent development and ...icians and patients can now benefit from the TAXUS liberte for the treatment of coronary artery disease," sai...

Boston Scientific Receives Canadian Approval for TAXUS(R) Liberte(R) Stent System

...ch the product immediately in Canada. "The TAXUS liberte Stent is a major advance in stent development and ...th our proven paclitaxel-eluting technology, TAXUS liberte provides physicians with next-generation performan... Stents have been implanted worldwide. The TAXUS liberte Stent has previously been approved for sale in Eur...
Other Tags
(Date:8/27/2015)... Angeles, CA (PRWEB) , ... August 27, 2015 , ... ... Association and the American Heart Association have released new guidelines to educate doctors and ... the last update to these particular guidelines came in 2007, so the new version ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Thriveology Founders, ... the featured speakers at The Amazing Aging Expo in Denver, Colorado on Saturday, August ... doctors are consistently featured in media outlets as health authorities, and will present a ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... the exploding legal marijuana industry with the launch of its Doobster platform, a ... marijuana to order products from their smart phones and tablets. Well, Doobster, ...
(Date:8/27/2015)... ... August 27, 2015 , ... About 10 percent of mothers ... Gulf Coast, killing more than 1,800 people, displacing hundreds of thousands and causing ... University study. , While most people don’t develop persistent depression after a major ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Naderi Center is proud to ... a cutting-edge, noninvasive procedure to improve submental fat. The first and only Food ... without surgery. Dr. Kulak is the only Board Certified surgeon in the D.C., ...
Breaking Medicine News(10 mins):Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:Internationally-renowned Naturopathic Doctor and Chiropractor Team up to Reveal Secrets of Avoiding Disease 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 4Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 5Health News:About 10 Percent of Mothers Experienced Depression Two Years After Hurricane Katrina, New Study Shows 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3
(Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
(Date:7/30/2015)... , July 30, 2015 Cellecta, Inc., ... gene function analysis and biomarker discovery, announced the ... Knockout Library targeting all human protein coding genes. ... "knock out" a gene,s function. Cellecta,s new Human ... throughput screening tool so that researchers can investigate ...
(Date:7/27/2015)... July 27, 2015   Zynx Health ™, ... clinical improvement solutions, today announced that its ... available on Android smartphones and tablets. With this ... organizations can use ZynxCarebook to securely exchange messages ... streamline care transitions to other care settings, and ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
Other Contents